News

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms of COVID-19 – a…
Read More...

Boehringer Ingelheim announced that the European Commission (EC) has approved an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial…
Read More...

Orchard Therapeutics announced that the company has entered into two worldwide royalty-bearing license agreements with GlaxoSmithKline plc (GSK) for use of their proprietary lentiviral…
Read More...

BioAegis Therapeutics Inc., announces that it received regulatory clearance from The Spanish Agency for Medicines and Health Products (AEMPS) for its Phase 2 Proof of Concept study of…
Read More...

Novocure announced it has entered into a clinical trial collaboration agreement with MSD (a tradename of Merck & Co., Inc.), through a subsidiary, to develop Tumor Treating Fields…
Read More...

Sanofi and The University of Texas MD Anderson Cancer Center announced a five-year strategic collaboration to accelerate the development of investigational treatments, including…
Read More...

Fate Therapeutics, Inc. announced that the Company entered into an exclusive license agreement with Baylor College of Medicine covering alloimmune defense receptors, a first-in-class…
Read More...

Medicago, a biopharmaceutical company headquartered in Quebec City, began Phase I clinical trials for its plant-derived COVID-19 vaccine candidate yesterday, administering the first…
Read More...

Roche and Blueprint Medicines Corporation announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and…
Read More...

The Hackensack Meridian Center for Discovery and Innovation (CDI) has struck a research collaboration with Merck to investigate drugs for treating COVID-19. The CDI will work with…
Read More...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA (guselkumab) for adult patients with active…
Read More...

Inflazome, the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, today announces that it has been granted Orphan Drug Designation by the…
Read More...

Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, has announced that it has commenced a Post Marketing Surveillance (PMS) study on FabiFlu to closely…
Read More...

Rocket Pharmaceuticals, Inc. announces that the first patient has received investigational therapy in the open-label, Phase 1 clinical trial of RP-L301, the Company’s lentiviral vector…
Read More...

Ovid Therapeutics Inc. and Angelini Pharma S.p.A. announced an agreement in which Angelini Pharma will be responsible to develop, manufacture and commercialize OV101 (gaboxadol) for the…
Read More...

Revitope Oncology Inc. and Junshi Biosciences announced the companies have entered into a strategic research collaboration. Revitope will leverage its proprietary protein engineering…
Read More...

Merus N.V. and Caris Life Sciences announced a collaboration to detect neuregulin 1 (NRG1) fusions in cancer patients. Under the agreement, Caris has agreed to perform whole exome…
Read More...

Pfizer Inc. and BioNTech SE announced that two of the companies’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2) being…
Read More...

Roche announced results from the second interim analysis of the phase IIIb STASEY study, which reinforce the safety profile of Hemlibra (emicizumab) characterised in the phase III HAVEN…
Read More...

Roche announced that the Phase III IMagyn050 study showed that the addition of Tecentriq (atezolizumab) to Avastin (bevacizumab), paclitaxel and carboplatin did not meet its primary…
Read More...